

# Myelofibrosis Therapeutics Market - 2023-2031

<https://marketpublishers.com/r/MA0B3F0B6F84EN.html>

Date: November 2025

Pages: 223

Price: US\$ 2,999.00 (Single User License)

ID: MA0B3F0B6F84EN

## Abstracts

The Myelofibrosis Therapeutics Market was valued at US\$ 2.80 billion in 2023 and is anticipated to reach US\$ 6.59 billion by 2031, at a CAGR of 0.076 from 2026 to 2032.

The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the Myelofibrosis Therapeutics Market.

This report delivers a comprehensive overview of the Myelofibrosis Therapeutics Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Myelofibrosis Therapeutics Market. The Myelofibrosis Therapeutics Market size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for 2023–2031.

Myelofibrosis Therapeutics Market Scope:

By Type

Primary Myelofibrosis

Secondary Myelofibrosis

By Therapy Type

Targeted Therapy

Surgery

Immunomodulators

Androgens

Cytoreductive Drugs

Others

By Gender

Male

Female

By End User

Hospitals & Clinics

Specialty Centers

Academia and Research Institutes

Others

Key Players

GSK plc.

CTI BIOPHARMA CORP.

Bristol-Myers Squibb Company.

Teva Pharmaceuticals USA, Inc.

Incyte.

Endo, Inc.

AdvaCare Pharma.

Aetos Pharma Private Limited.

F. Hoffmann-La Roche Ltd

TAJ PHARMA GROUP

## Major Highlights

This report delivers a comprehensive overview of the Myelofibrosis Therapeutics Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Myelofibrosis Therapeutics Market. The Myelofibrosis Therapeutics Market size, estimates, and forecasts are provided in terms of output/shipments (K Sqm) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for 2023–2031.

This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.

## Regional Analysis:

North America (U.S., Canada, Mexico)

Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

South America (Colombia, Brazil, Argentina, Rest of South America)

Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

## Partner Identification

Increase Your Customer Base by 3X using our Partner Identification tool

Uncover strategic collaboration opportunities with DataM vetted partners aligned to your ecosystem.

Identify high potential M&A targets based on synergies, market positioning and growth trajectory.

Prioritize partners by strategic fit rather than general capability.

## Why Choose DataM?

**Data-Driven Insights:** Dive into detailed analyses with granular insights such as pricing, market shares and value chain evaluations, enriched by interviews with industry leaders and disruptors.

**Post-Purchase Support and Expert Analyst Consultations:** As a valued client, gain direct access to our expert analysts for personalized advice and strategic guidance, tailored to your specific needs and challenges.

**White Papers and Case Studies:** Benefit quarterly from our in-depth studies related to your purchased titles, tailored to refine your operational and marketing strategies for maximum impact.

**Annual Updates on Purchased Reports:** As an existing customer, enjoy the privilege of annual updates to your reports, ensuring you stay abreast of the latest market insights and technological advancements. Terms and conditions

apply.

**Specialized Focus on Emerging Markets:** DataM differentiates itself by delivering in-depth, specialized insights specifically for emerging markets, rather than offering generalized geographic overviews. This approach equips our clients with a nuanced understanding and actionable intelligence that are essential for navigating and succeeding in high-growth regions.

**Value of DataM Reports:** Our reports offer specialized insights tailored to the latest trends and specific business inquiries. This personalized approach provides a deeper, strategic perspective, ensuring you receive the precise information necessary to make informed decisions. These insights complement and go beyond what is typically available in generic databases.

## Target Audience 2026

Manufacturers/ Buyers

Industry Investors/Investment Bankers

Research Professionals

Emerging Companies

## Contents

### **1. METHODOLOGY AND SCOPE**

- 1.1. Research Methodology
- 1.2. Research Objective and Scope of the Report

### **2. DEFINITION AND OVERVIEW**

### **3. EXECUTIVE SUMMARY**

- 3.1. Snippet by Type
- 3.2. Snippet by Therapy Type
- 3.3. Snippet by Gender
- 3.4. Snippet by End User

### **4. DYNAMICS**

- 4.1. Impacting Factors
  - 4.1.1. Drivers
    - 4.1.1.1. Rising product development and pipeline drugs
    - 4.1.1.2. Rising prevalence of myelofibrosis
  - 4.1.2. Restraints
    - 4.1.2.1. High cost of treatment
  - 4.1.3. Opportunity
  - 4.1.4. Impact Analysis

### **5. INDUSTRY ANALYSIS**

- 5.1. Porter's Five Force Analysis
- 5.2. Supply Chain Analysis
- 5.3. Pricing Analysis
- 5.4. Regulatory Analysis
- 5.5. Unmet Needs
- 5.6. PESTEL Analysis
- 5.7. Patent Analysis
- 5.8. SWOT Analysis

### **6. COVID-19 ANALYSIS**

- 6.1. Analysis of COVID-19
  - 6.1.1. Scenario Before COVID
  - 6.1.2. Scenario During COVID
  - 6.1.3. Scenario Post COVID
- 6.2. Pricing Dynamics Amid COVID-19
- 6.3. Demand-Supply Spectrum
- 6.4. Government Initiatives Related to the Market During Pandemic
- 6.5. Manufacturers Strategic Initiatives
- 6.6. Conclusion

## **7. BY TYPE**

- 7.1. Introduction
  - 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  - 7.1.2. Market Attractiveness Index, By Type
- 7.2. Primary Myelofibrosis\*
  - 7.2.1. Introduction
  - 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 7.3. Secondary Myelofibrosis

## **8. BY THERAPY TYPE**

- 8.1. Introduction
  - 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
  - 8.1.2. Market Attractiveness Index, By Therapy Type
- 8.2. Targeted Therapy\*
  - 8.2.1. Introduction
  - 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  - 8.2.3. Ruxolitinib
  - 8.2.4. Fedratinib
  - 8.2.5. Pacritinib
  - 8.2.6. Momelotinib
- 8.3. Surgery
  - 8.3.1. Stem Cell Transplantation
  - 8.3.2. Splenectomy
- 8.4. Immunomodulators
- 8.5. Androgens
- 8.6. Cytoreductive Drugs

## 8.7. Others

## 9. BY GENDER

### 9.1. Introduction

9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Gender

9.1.2. Market Attractiveness Index, By Gender

### 9.2. Male\*

9.2.1. Introduction

9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)

### 9.3. Female

## 10. BY END USER

### 10.1. Introduction

10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

10.1.2. Market Attractiveness Index, By End User

### 10.2. Hospitals & Clinics\*

10.2.1. Introduction

10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)

### 10.3. Specialty Centers

### 10.4. Academia and Research Institutes

### 10.5. Others

## 11. COMPETITIVE LANDSCAPE

### 11.1. Competitive Scenario

### 11.2. Market Positioning/Share Analysis

### 11.3. Mergers and Acquisitions Analysis

## 12. COMPANY PROFILES

### 12.1. GSK plc.

12.1.1. Company Overview

12.1.2. Product Portfolio and Description

12.1.3. Financial Overview

12.1.4. Key Developments

### 12.2. CTI BIOPHARMA CORP.

### 12.3. Bristol-Myers Squibb Company.

- 12.4. Teva Pharmaceuticals USA, Inc.
- 12.5. Incyte.
- 12.6. Endo, Inc.
- 12.7. AdvaCare Pharma.
- 12.8. Aetos Pharma Private Limited.
- 12.9. F. Hoffmann-La Roche Ltd
- 12.10. TAJ PHARMA GROUP (LIST NOT EXHAUSTIVE)

### **13. APPENDIX**

- 13.1. About Us and Services
- 13.2. Contact Us

## I would like to order

Product name: Myelofibrosis Therapeutics Market - 2023-2031

Product link: <https://marketpublishers.com/r/MA0B3F0B6F84EN.html>

Price: US\$ 2,999.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/MA0B3F0B6F84EN.html>